Microbiome Center NL

Analyse en behandeling op maat 

Literatuur

1. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep [Internet]. 2006 [cited
2013 Dec 21];7:688–93. Available from: http://www.nature.com/embor/journal/v7/n7/full/7400731.html

2. Hooper LV, Littman DR, Macpherson AJ. Interactions Between the Microbiota and the Immune
System. Science [Internet]. 2012 [cited 2016 Nov 30];336:1268–73. Available from: http://science.sciencemag.org/content/336/6086/1268

3. Sommer F, Bäckhed F. The gut microbiota — masters of host development and physiology. NatRev Microbiol [Internet]. 2013 [cited 2016 Sep 9];11:227–38. Available from:http://www.nature.com/nrmicro/journal/v11/n4/abs/nrmicro2974.html

4. Ferreira CM, Vieira AT, Vinolo MAR, Oliveira FA, Curi R, Martins F dos S. The Central Role
of the Gut Microbiota in Chronic Inflammatory Diseases. J Immunol Res [Internet]. 2014 [cited
2018 Jan 30];2014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189530/

5. Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory
disease. BMJ [Internet]. 2018 [cited 2018 Jan 13];360:j5145. Available from:
http://www.bmj.com/content/360/bmj.j5145

6. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin
Immunopathol [Internet]. 2015 [cited 2018 Jan 14];37:47–55. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281375/

7. Machiels K, Joossens M, Sabino J, Preter VD, Arijs I, Eeckhaut V, Ballet V, Claes K, Immerseel
FV, Verbeke K, et al. A decrease of the butyrate-producing species Roseburia hominis and
Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut [Internet].
2014 [cited 2018 Jan 14];63:1275–83. Available from: http://gut.bmj.com/content/63/8/1275

8. Forbes JD, Van Domselaar G, Bernstein CN. The Gut Microbiota in Immune-Mediated
Inflammatory Diseases. Front Microbiol [Internet]. 2016 [cited 2018 Jan 14];7. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939298/

9. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada J-R.
Unstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission.
Am J Gastroenterol [Internet]. 2008 [cited 2018 Jan 14];103:643. Available from:
https://www.nature.com/articles/ajg200850131

10. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology [Internet]. 2015 [cited 2018 Jan 14];149:102-109.e6. Available from: http://www.gastrojournal.org/article/S0016-5085(15)00451-5/abstract

11. Ringel Y, Ringel-Kulka T. The Intestinal Microbiota and Irritable Bowel Syndrome. J Clin
Gastroenterol. 2015;49 Suppl 1:S56-59.

12. Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr
Gastroenterol Rep. 2013;15:323.

13. Hong SN, Rhee P-L. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol WJG [Internet]. 2014 [cited 2018 Jan 30];20:2470–81. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949257/

14. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel
syndrome: Updated systematic review with meta-analysis. World J Gastroenterol WJG
[Internet]. 2015 [cited 2018 Jan 30];21:3072–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356930/

15. Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel
syndrome symptoms: A bring up to date meta-analysis. Rev Espanola Enfermedades Dig
Organo Of Soc Espanola Patol Dig. 2013;105:19–36.

16. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EMM.
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Gut. 2010;59:325–32.

17. Fernández-Bañares F, Accarino A, Balboa A, Domènech E, Esteve M, Garcia-Planella E,
Guardiola J, Molero X, Rodríguez-Luna A, Ruiz-Cerulla A, et al. Chronic diarrhoea: Definition,
classification and diagnosis. Gastroenterol Hepatol Engl Ed [Internet]. 2016 [cited 2018 Feb
3];39:535–59. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2444382416300724

18. Swidsinski A, Loening–Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of Fecal
Microbiota in Healthy Subjects and Patients With Chronic Idiopathic Diarrhea.
Gastroenterology [Internet]. 2008 [cited 2018 Feb 3];135:568-579.e2. Available from:
http://www.gastrojournal.org/article/S0016-5085(08)00669-0/abstract

19. Scaldaferri F, Pizzoferrato M, Pecere S, Forte F, Gasbarrini A. Bacterial Flora as a Cause or
Treatment of Chronic Diarrhea. Gastroenterol Clin North Am [Internet]. 2012 [cited 2018 Feb
3];41:581–602. Available from: http://www.sciencedirect.com/science/article/pii/S0889855312000702

20. Clauw DJ. Fibromyalgia: A Clinical Review. JAMA [Internet]. 2014 [cited 2018 Feb
3];311:1547. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2014.3266

21. Kravitz HM, Katz RS. Fibrofog and fibromyalgia: a narrative review and implications for
clinical practice. Rheumatol Int. 2015;35:1115–25.

22. Clauw DJ, D’Arcy Y, Gebke K, Semel D, Pauer L, Jones KD. Normalizing fibromyalgia as a
chronic illness. Postgrad Med [Internet]. 2018 [cited 2018 Feb 3];130:9–18. Available from:
https://doi.org/10.1080/00325481.2018.1411743

23. Galland L. The Gut Microbiome and the Brain. J Med Food [Internet]. 2014 [cited 2018 Feb
3];17:1261–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259177/

24. Zhu X, Han Y, Du J, Liu R, Jin K, Yi W, Zhu X, Han Y, Du J, Liu R, et al. Microbiota-gut-brain
axis and the central nervous system. Oncotarget [Internet]. 2017 [cited 2018 Feb 3];8:53829–38.
Available from: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=17754&path[]=56860

25. Othman M, Agüero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr
Opin Gastroenterol [Internet]. 2008 [cited 2018 Feb 3];24:11. Available from: https://journals.lww.com/cogastroenterology/Abstract/2008/01000/Alterations_in_intestinal_microbial_flora_and.4.aspx

26. Malatji BG, Meyer H, Mason S, Engelke UFH, Wevers RA, van Reenen M, Reinecke CJ. A
diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study
of selected patients and controls. BMC Neurol [Internet]. 2017 [cited 2018 Feb 3];17. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426044/

27. Bested AC, Marshall LM. Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome:
an evidence-based approach to diagnosis and management by clinicians. Rev Environ Health.
2015;30:223–49.

28. Mensah FKF, Bansal AS, Ford B, Cambridge G. Chronic fatigue syndrome and the immune
system: Where are we now? Neurophysiol Clin Clin Neurophysiol. 2017;47:131–8.

29. Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity
and altered composition of the gut microbiome in individuals with myalgic
encephalomyelitis/chronic fatigue syndrome. Microbiome [Internet]. 2016 [cited 2018 Feb 4];4.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918027/

30. Mandarano AH, Giloteaux L, Keller BA, Levine SM, Hanson MR. Eukaryotes in the gut
microbiota in myalgic encephalomyelitis/chronic fatigue syndrome. PeerJ [Internet]. 2018
[cited 2018 Feb 4];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784577/

31. Maes M, Twisk FNM, Kubera M, Ringel K, Leunis J-C, Geffard M. Increased IgA responses to
the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated
immunity in chronic fatigue syndrome. J Affect Disord. 2012;136:909–17.

32. Morris G, Berk M, Carvalho AF, Caso JR, Sanz Y, Maes M. The Role of Microbiota and
Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes
with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue
Syndrome. Curr Pharm Des. 2016;22:6058–75.

33. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab
[Internet]. 2010 [cited 2018 Feb 4];7:79. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964729/

34. Borody TJ, Nowak A, Finlayson S. The GI microbiome and its role in Chronic Fatigue
Syndrome: A summary of bacteriotherapy. J Australas Coll Nutr Environ Med [Internet]. 2012
[cited 2018 Feb 4];31:3. Available from: http://search.informit.com.au/documentSummary;dn=119626231492520;res=IELNZC

35. Janssen AWF, Kersten S. The role of the gut microbiota in metabolic health. FASEB J Off Publ
Fed Am Soc Exp Biol. 2015;29:3111–23.

36. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin
AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut
microbiome. Nature [Internet]. 2013 [cited 2013 Dec 27];559–63. Available from:
http://www.nature.com/nature/journal/vaop/ncurrent/full/nature12820.html

37. Shulzhenko N, Morgun A, Hsiao W, Battle M, Yao M, Gavrilova O, Orandle M, Mayer L,
Macpherson AJ, McCoy KD, et al. Crosstalk between B lymphocytes, microbiota and the
intestinal epithelium governs immunity versus metabolism in the gut. Nat Med [Internet]. 2011
[cited 2016 Nov 30];17:1585–93. Available from: http://www.nature.com/nm/journal/v17/n12/full/nm.2505.html

38. Barlow GM, Yu A, Mathur R. Role of the Gut Microbiome in Obesity and Diabetes Mellitus.
Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr. 2015;30:787–97.

39. Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating Causality of Gut
Microbiota in Obesity and Diabetes in Humans. Endocr Rev. 2017;

40. Marotz CA, Zarrinpar A. Treating Obesity and Metabolic Syndrome with Fecal Microbiota
Transplantation. Yale J Biol Med [Internet]. 2016 [cited 2018 Mar 23];89:383–8. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045147/

41. Vrieze A, Nood EV, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga–Thie
GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of Intestinal Microbiota From Lean
Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology
[Internet]. 2012 [cited 2018 Mar 23];143:913-916.e7. Available from:
http://www.gastrojournal.org/article/S0016-5085(12)00892-X/fulltext

42. Mazidi M, Rezaie P, Kengne AP, Mobarhan MG, Ferns GA. Gut microbiome and metabolic
syndrome. Diabetes Metab Syndr. 2016;10:S150-157.

43. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and
metabolic syndrome. World J Gastroenterol WJG [Internet]. 2014 [cited 2018 Mar
24];20:16079–94. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239493/

44. Gomes AC, Bueno AA, de Souza RGM, Mota JF. Gut microbiota, probiotics and diabetes. Nutr
J [Internet]. 2014 [cited 2018 Feb 28];13:60. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078018/

45. Dunne JL, Triplett EW, Gevers D, Xavier R, Insel R, Danska J, Atkinson MA. The intestinal
microbiome in type 1 diabetes. Clin Exp Immunol [Internet]. 2014 [cited 2018 Mar 23];177:30–
7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089152/

46. Semenkovich CF, Danska J, Darsow T, Dunne JL, Huttenhower C, Insel RA, McElvaine AT,
Ratner RE, Shuldiner AR, Blaser MJ. American Diabetes Association and JDRF Research
Symposium: Diabetes and the Microbiome. Diabetes [Internet]. 2015 [cited 2018 Feb
28];64:3967–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876761/

47. Knip M, Honkanen J. Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome. Curr
Diab Rep. 2017;17:105.

48. Haluzík M, Kratochvílová H, Haluzíková D, Mráz M. Gut as an emerging organ for the
treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions. J
Endocrinol [Internet]. 2018 [cited 2018 Feb 27];237:R1–17. Available from:
http://joe.endocrinology-journals.org/content/237/1/R1

49. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63:1513–21.

50. Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol
Arch Intern Med [Internet]. 2015 [cited 2018 Feb 28];125:803–13. Available from:
http://pamw.pl/en/node/3156

51. Singh V, Yeoh BS, Vijay-Kumar M. Gut Microbiome as a Novel Cardiovascular Therapeutic
Target. Curr Opin Pharmacol [Internet]. 2016 [cited 2018 Mar 25];27:8–12. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808470/

52. Yamashita T, Kasahara K, Emoto T, Matsumoto T, Mizoguchi T, Kitano N, Sasaki N, Hirata K.
Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic
Cardiovascular Diseases. Circ J [Internet]. 2015 [cited 2018 Mar 25];79:1882–90. Available
from: https://www.jstage.jst.go.jp/article/circj/79/9/79_CJ-15-0526/_article

53. Lau K, Srivatsav V, Rizwan A, Nashed A, Liu R, Shen R, Akhtar M. Bridging the Gap between
Gut Microbial Dysbiosis and Cardiovascular Diseases. Nutrients [Internet]. 2017 [cited 2018 Feb 27]; 9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579652/

54. Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin
Invest [Internet]. 2014 [cited 2018 Mar 25];124:4204–11. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215189/

55. Dinakaran V, Rathinavel A, Pushpanathan M, Sivakumar R, Gunasekaran P, Rajendhran J.
Elevated Levels of Circulating DNA in Cardiovascular Disease Patients: Metagenomic Profiling
of Microbiome in the Circulation. PLoS ONE [Internet]. 2014 [cited 2018 Mar 25];9. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136842/

56. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, et al. Gut microbiota
dysbiosis contributes to the development of hypertension. Microbiome [Internet]. 2017 [cited
2018 Mar 25];5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286796/

57. Ettinger G, MacDonald K, Reid G, Burton JP. The influence of the human microbiome and
probiotics on cardiovascular health. Gut Microbes [Internet]. 2014 [cited 2018 Mar 25];5:719–
28. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615746/

58. Gershon MD. The enteric nervous system: a second brain. Hosp Pract 1995. 1999;34:31–2, 35–
8, 41-42 passim.

59. Ochoa-Repáraz J, Kasper LH. The Second Brain: Is the Gut Microbiota a Link Between
Obesity and Central Nervous System Disorders? Curr Obes Rep [Internet]. 2016 [cited 2018
May 22];5:51–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798912/

60. Dinan TG, Cryan JF. Melancholic microbes: a link between gut microbiota and depression?
Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2013;25:713–9.

61. Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on
depression. Curr Opin Psychiatry. 2015;28:1–6.

62. Kim N, Yun M, Oh YJ, Choi H-J. Mind-altering with the gut: Modulation of the gut-brain axis
with probiotics. J Microbiol Seoul Korea. 2018;56:172–82.

63. Mangiola F, Ianiro G, Franceschi F, Fagiuoli S, Gasbarrini G, Gasbarrini A. Gut microbiota in
autism and mood disorders. World J Gastroenterol [Internet]. 2016 [cited 2018 May 24] ;22:361–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698498/

64. Lv F, Chen S, Wang L, Jiang R, Tian H, Li J, Yao Y, Zhuo C. The role of microbiota in the
pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting
microbiota as a treatment option. Oncotarget [Internet]. 2017 [cited 2018 May 24];8:100899–
907. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725071/

65. Huang R, Wang K, Hu J. Effect of Probiotics on Depression: A Systematic Review and Meta-
Analysis of Randomized Controlled Trials. Nutrients [Internet]. 2016 [cited 2018 May 24];8.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997396/

66. Pelsser LMJ. ADHD, a Food-Induced Hypersensitivity Syndrome: in Quest of a Cause The
effects of a restricted elimination diet (RED) on ADHD, ODD and comorbid somatic
complaints, and a preliminary survey of the mechanisms of an RED. [Nijmegen]: Radboud
Universiteit; 2011.

67. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gutmicrobiota-
brain axis and effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther [Internet]. 2015 [cited 2018 May 26];37:984–95. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458706/

68. Cenit MC, Nuevo IC, Codoñer-Franch P, Dinan TG, Sanz Y. Gut microbiota and attention
deficit hyperactivity disorder: new perspectives for a challenging condition. Eur Child Adolesc
Psychiatry. 2017;26:1081–92.

69. Aarts E, Ederveen THA, Naaijen J, Zwiers MP, Boekhorst J, Timmerman HM, Smeekens SP,
Netea MG, Buitelaar JK, Franke B, et al. Gut microbiome in ADHD and its relation to neural
reward anticipation. PLoS ONE [Internet]. 2017 [cited 2018 May 26];12. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581161/

70. Jiang H-Y, Zhou Y-Y, Zhou G-L, Li Y-C, Yuan J, Li X-H, Ruan B. Gut microbiota profiles in
treatment-naïve children with attention deficit hyperactivity disorder. Behav Brain Res.
2018;347:408–13.

71. Pärtty A, Kalliomäki M, Wacklin P, Salminen S, Isolauri E. A possible link between early
probiotic intervention and the risk of neuropsychiatric disorders later in childhood: a
randomized trial. Pediatr Res. 2015;77:823–8.

72. Madore C, Leyrolle Q, Lacabanne C, Benmamar-Badel A, Joffre C, Nadjar A, Layé S.
Neuroinflammation in Autism: Plausible Role of Maternal Inflammation, Dietary Omega 3, and
Microbiota. Neural Plast [Internet]. 2016 [cited 2018 May 26];2016. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093279/

73. Mayer EA, Padua D, Tillisch K. Altered brain-gut axis in autism: comorbidity or causative
mechanisms? BioEssays News Rev Mol Cell Dev Biol. 2014;36:933–9.

74. Navarro F, Liu Y, Rhoads JM. Can probiotics benefit children with autism spectrum disorders?
World J Gastroenterol [Internet]. 2016 [cited 2018 May 26];22:10093–102. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155168/

75. Kang D-W, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, Khoruts A, Geis E,
Maldonado J, McDonough-Means S, et al. Microbiota Transfer Therapy alters gut ecosystem
and improves gastrointestinal and autism symptoms: an open-label study. Microbiome
[Internet]. 2017 [cited 2018 May 26];5. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264285/

76. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato
W, Kim S-W, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a
Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS ONE
[Internet]. 2015 [cited 2018 May 26];10. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569432/

77. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MMP, Luckey DH, Marietta EV,
Jeraldo PR, Chen X, et al. Multiple sclerosis patients have a distinct gut microbiota compared to
healthy controls. Sci Rep [Internet]. 2016 [cited 2018 May 26];6. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921909/

78. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme
Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T
cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A [Internet]. 2017
[cited 2018 May 27];114:10713–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635915/

79. Branton WG, Lu JQ, Surette MG, Holt RA, Lind J, Laman JD, Power C. Brain microbiota
disruption within inflammatory demyelinating lesions in multiple sclerosis. Sci Rep [Internet].
2016 [cited 2018 May 26];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125007/

80. Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Lokhande H,
Gandhi R, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann
Neurol. 2018;

81. Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-
Ebrahimi M, Jafari P, Asemi Z. Clinical and metabolic response to probiotic supplementation
in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin
Nutr Edinb Scotl. 2017;36:1245–9.

82. Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook S, Gandhi R,
Glanz B, et al. Investigation of probiotics in multiple sclerosis. Mult Scler Houndmills
Basingstoke Engl. 2018;24:58–63.

83. Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson’s disease. Parkinsonism
Relat Disord. 2017;38:1–7.

84. Felice VD, Quigley EM, Sullivan AM, O’Keeffe GW, O’Mahony SM. Microbiota-gut-brain
signalling in Parkinson’s disease: Implications for non-motor symptoms. Parkinsonism Relat
Disord. 2016;27:1–8.

85. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM,
Asthana S, Zetterberg H, Blennow K, et al. Gut microbiome alterations in Alzheimer’s disease.
Sci Rep [Internet]. 2017 [cited 2018 May 27];7. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648830/

86. Zhao Y, Jaber V, Lukiw WJ. Secretory Products of the Human GI Tract Microbiome and Their
Potential Impact on Alzheimer’s Disease (AD): Detection of Lipopolysaccharide (LPS) in AD
Hippocampus. Front Cell Infect Microbiol [Internet]. 2017 [cited 2018 May 27];7. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504724/

87. Lin L, Zheng LJ, Zhang LJ. Neuroinflammation, Gut Microbiome, and Alzheimer’s Disease.
Mol Neurobiol. 2018;

88. Kaeberlein M, Rabinovitch PS, Martin GM. Healthy aging: the ultimate preventative medicine.
Science [Internet]. 2015 [cited 2018 May 27];350:1191–3. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793924/

89. Calvani R, Picca A, Lo Monaco MR, Landi F, Bernabei R, Marzetti E. Of Microbes and Minds:
A Narrative Review on the Second Brain Aging. Front Med [Internet]. 2018 [cited 2018 May
27];5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840854/

90. Vaiserman AM, Koliada AK, Marotta F. Gut microbiota: A player in aging and a target for antiaging
intervention. Ageing Res Rev. 2017;35:36–45.

91. Mello AM, Paroni G, Daragjati J, Pilotto A. Gastrointestinal Microbiota and Their Contribution
to Healthy Aging. Dig Dis Basel Switz. 2016;34:194–201.

92. Rondanelli M, Giacosa A, Faliva MA, Perna S, Allieri F, Castellazzi AM. Review on microbiota
and effectiveness of probiotics use in older. World J Clin Cases WJCC [Internet]. 2015 [cited
2018 May 27];3:156–62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317609/

93. Diamanti AP, Manuela Rosado M, Laganà B, D’Amelio R. Microbiota and chronic
inflammatory arthritis: an interwoven link. J Transl Med [Internet]. 2016 [cited 2018 Feb 3];14.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973033/